SAN DIEGO, May 22, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the thirteen abstracts relating to its proprietary

New research being presented at Digestive Disease Week® (DDW) offers key insights into the prevention and treatment of bowel diseases, which affect millions of people worldwide.

The American College of Rheumatology (ACR) has released the 2012 recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) and biologic agents in the treatment of rheumatoid arthritis (RA).

INDIANAPOLIS, March 28, 2012 /PRNewswire/ -- New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's (NYSE: LLY) ixekizumab (pronounced

ABBOTT PARK, Ill., March 15, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational